Over the past 4 decades, effective therapies for AF have evolved, 10, 11 most notably, the use of oral anticoagulant medications to prevent stroke. [12] [13] [14] [15] [16] However; given regional differences in healthcare systems, resource availability, expertise, and physician preferences, these therapies are often applied heterogeneously. 17 The purpose of this study was to evaluate regional differences in the risk factors of patients with AF and to describe the differences in management.
Methods
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) AF registry enrolled patients who presented to an emergency department (or equivalent acute-care setting) with AF or atrial flutter, either as the primary reason for their visit or as a secondary diagnosis. Consecutive screening of patients was strongly encouraged, although the possibilities for consecutive enrolment were limited owing to practical constraints, such as the availability of research staff in emergency departments. Centers were also to enroll patients as rapidly as possible and avoid obvious biases in the way patients were identified, such as enrolling only patients who had been admitted to hospital. Where possible, patients with AF were also identified from hospital databases of presenting diagnoses in the emergency department and from systematic review of ECGs conducted in the emergency department. All patients gave written consent for study participation; this was obtained in person by study personnel or via a mailed information and consent form sent to suitable patients identified from administrative records.
A total of 164 sites participated in the AF registry, representing 46 countries from all inhabited continents (Table 1) . Countries were grouped into 9 geographic regions, and the income status of countries was defined by the use of the 2011 World Bank definitions 18 : North America, South America, Western Europe (including Australia), Eastern Europe, the Middle East (including North Africa and Turkey), Africa, India, China, and Southeast Asia. Wherever possible, registry sites in each region were selected to include large and small hospitals, rural and urban locations, academic and community settings, and both public and private hospitals. The study design and protocol were developed by the principal investigators, and the study was coordinated and data were managed by the Population Health Research Institute at McMaster University in Hamilton, Canada, with additional regional coordination centers in Sao Paulo, Brazil; Beijing, China; Bangalore, India; Prague, Czech Republic; and Seoul, South Korea.
Clinical data were collected by interviews with patients, review of medical records, and contacts with treating physicians. The diagnosis of all medical conditions including type of AF was based on the clinical record. Persistent AF was defined as episodes that do not terminate spontaneously but do convert with either electric or pharmacological cardioversion, paroxysmal AF was defined as episodes terminating spontaneously, and permanent AF was defined as an episode that does not terminate either spontaneously or with electric or chemical cardioversion, or where cardioversion has not been attempted. Lone AF was in the database defined as AF occurring in individuals <60 years of age, without concomitant cardiovascular disease (including hypertension), pulmonary disease, hyperthyroidism, or recent cardiac surgery. For patients on oral anticoagulation, the 3 most recent international normalized ratio (INR) values before the emergency department visit were collected. There were no biochemical or genetic testing and no central review of imaging studies.
The clinical characteristics of patients and their medical treatment for cardiovascular diseases including AF are presented for each region. Continuous variables were compared by using an analysis of variance and categorical variables using the χ 2 test. An overall P value was initially computed to test the hypothesis that no difference existed across all regions with respect to each patient characteristic; the significance level was set at 0.001. Each individual region was then compared against the other regions for each characteristic for a further understanding of the existing global differences, where a prespecified significance level of 0.005 was used. The study protocol predefined 10 clinical characteristics for the primary analysis: age, hypertension, diabetes mellitus, coronary artery disease, left ventricular dysfunction, heart failure, valvular heart disease, stroke/transient ischemic attack, obesity, and alcohol use, based on previous studies of risk factors. 9, 19 Only ≤3 patients had missing data on each of the first eight of these clinical characteristics. Five hundred ninety-four patients (3.86%) had missing data for the calculation of body mass index, and 1333 (8.66%) patients either had missing data or abstained from answering questions about alcohol consumption. We also calculated the CHADS 2 stroke risk score, 20 which assigns 1 point for a history of congestive heart failure, hypertension, age ≥75 years, or diabetes mellitus, and 2 points for previous stroke or transient ischemic attack. The use of 
Results
A total of 15 400 patients with AF (including atrial flutter in 2.3% of the patients) were enrolled at participating emergency departments between September 2008 and April 2011 ( Table 2) . AF was the primary reason for visiting the emergency department in 44.4% of cases. In total, 27.7% of the patients had their first documented episode, in 7.6% of patients it was unknown/uncertain if they had a previous AF diagnosis, whereas a previous history of AF was found in 64.6% of the patients; of those patients, AF was classified as permanent in 50.5%, persistent in 22.6%, and paroxysmal in 26.9%. There was a substantial variation in the type of AF between the regions, with almost equal distribution between paroxysmal, persistent, and permanent AF in Western Europe, whereas in Africa and the Middle East, 81.4% and 71.7%, respectively, of the patients had permanent AF (Table 2) . At the conclusion of the emergency department visit, 66.1% of patients were admitted to the hospital, 33.7% of patients were discharged home, and 0.2% of patients died in the emergency department.
The average age of the registry patients was 65.9, standard deviation (SD) 14.8 years, with significantly higher average ages in patients enrolled in North and South America, Western and Eastern Europe, China, and Southeast Asia, with the highest age in North America 70.1, SD 13.4 years ( Table 2) . By comparison, patients in India, the Middle East, and Africa were on average ≈10 to 12 years younger than patients in the aforementioned 6 regions. Overall, 4.2% of patients were ≤35 years of age, and 28.7% were >75 years of age. In total, 52.8% of the patients were men, with the highest proportions of men in Western Europe (61.2%) and North America (58.3%), and the lowest proportions in China (45.5%) and Africa (46.9%).
Cardiovascular Conditions
Overall, hypertension was the most prevalent AF risk factor and was present in 62.0% of patients. Patients in Eastern Europe had the highest prevalence of hypertension (80.7%), whereas those in Western Europe, India, China, Southeast Asia, the Middle East, and Africa, had a lower prevalence, with the lowest prevalence of 41.6% in India ( Table 2) . Underreporting of hypertension appeared uncommon, because, globally, <4% of patients without a reported history of hypertension had a baseline blood pressure >160/100 (Table 2) .
Overall, a history of stroke or transient ischemic attack was present in 13.8% of the patients. The highest rates were seen in China (18.8%) and Southeast Asia (22.1%), whereas the rate of previous stroke or transient ischemic attack was substantially lower (7.4%) in India ( Table 2 ). In total, 14.4% of all patients had a history of myocardial infarction, with similar rates in all regions, with the exception of substantially lower rates in China (7.3%) and Africa (5.5%). A history of heart failure was present in one-third of the patients with AF and ranged in prevalence from 17.7% of patients in India to 63.8% of patients in Africa. Among patients with a history of heart failure, the prevalence of systolic left ventricular dysfunction varied from 36.2% in North America to >60% in Africa, South America, and the Middle East, P<0.0001. Valvular heart disease was most common in India (46.7%) and Africa (32.6%), but much less common in Eastern Europe (10.7%) and Western Europe (8.8%; Table 2 ). Rheumatic heart disease was present in 11.6% of the patients, but only in 1.5% of patients in Western Europe and 2.2% of patients in North America, in comparison with >15% in Africa, the Middle East, and China and 31.5% in India (Table 2, Figure 1 ). In total, 4.7% of the patients had a pacemaker with the highest proportions in North America (8.6%), Western Europe (7.9%), and Eastern Europe (6.9%), but <2% of the patients in India and Africa had a pacemaker ( Table 2 ). Recent cardiac surgery and congenital heart disease were uncommon among AF patients worldwide: present in only 1.2% and 2.2% of cases, respectively.
The average CHADS 2 risk score was 1.8 (SD 1.4), the highest score was found in Eastern Europe (2.3, SD 1.2) and lower risk in India, China, the Middle East, Africa, and Western Europe with the lowest score in India (1.1, SD 1.1; Table 2 ). A history of major bleeding was uncommon (3.8%), with the highest rate in North America (7.9%) and the lowest rate in India (1.5%).
Lone AF (ie, patients <60 years of age without predisposing conditions) was uncommon, representing 10.7% of patients worldwide with even lower proportions in South America, Eastern Europe, Africa, and India (Table 2 ).
Other Concomitant Conditions
Diabetes mellitus was present in 21.8% of patients with AF, with rates ranging from 15.5% in India to 36.2% in the Middle East; and 11.5% of the patients had chronic obstructive pulmonary disease, ranging from <5% in India and Africa to 23.4% in Eastern Europe (Table 2 ). Obstructive sleep apnea was found in 3.9% of the patients and obesity (body mass index ≥35) in 7.2% of the patients; both conditions were more common in North America, 10.1% and 15.2% of patients, respectively, than anywhere else in the world (Table 2) .
Hyperthyroidism was found in 3.7% of the patients, but it was more common in Eastern Europe (7.0%) and Southeast Asia (5.4%). In Africa, >8% of AF cases were associated with HIV, pericarditis, endomyocardial fibrosis, or active tuberculosis; whereas these 4 conditions were significantly less common elsewhere (Table 2 ). Reported alcohol intake was highest in Western Europe and North America. Overall, 17.0% of AF patients had a history of tobacco use, and the prevalence was greatest in North America, China, Southeast Asia, and the Middle East and lowest in India (7.5%).
Medication in Patients With a Previous History of AF or Other Predisposing Conditions
In total, 30.2% of the patients received oral anticoagulants (ie, vitamin K antagonists), ranging from 13.5% in China to 43.5% in North America (Table 3) . In patients with a previous history of AF and a CHADS 2 risk score of ≥2 but without a history of rheumatic fever, 44.1% were treated with an oral anticoagulant at the time of presentation to the emergency department: 65.7% of patients in North America and 63.2% (Figure 2 ). Corresponding rates in other regions varied significantly from 11.0% to 56%. Among patients with rheumatic heart disease, the use of oral anticoagulant medications ranged from 40% in China, 50% in Africa, to >85% in Western Europe (Figure 2 ). INR results were available in 82.1% of the patients on oral anticoagulant treatment.
The proportion of INR values between 2.0 and 3.0 was highest in Western Europe (67%) and lowest in India (35%; Figure 3 ). The mean time in the therapeutic range, calculated by the Rosendaal method 22 for 78.2% of the patients with available INR results, was 62.4% in Western Europe, 50.9% in North America, but only between 32% and 40% in India, China, Southeast Asia, and Africa (Table 3) .
Approximately one-third of patients with a previous history of AF were treated with aspirin at the time of presentation to the emergency department, ranging from 24.1% in India and 27.2% in Africa to >40% in North and South America and 48.4% in China (Table 3) . Overall, 7.7% of AF patients were receiving treatment with clopidogrel, with higher proportions in India (14.2%) and the Middle East (10.7%).
The most commonly used other pharmacological treatments in patients with previous AF were diuretics, globally in 43.3% of the patients, ranging from one-third of patients in China and Southeast Asia to ≈50% of the patients in South America, Eastern Europe, and Africa (Table 3 ). In total, almost 30% of the patients received an angiotensin-converting enzyme inhibitor, but <15% in India and Southeast Asia, and >50% in Eastern Europe; and ≈15% had an angiotensin receptor blocker, with the lowest rates in Africa (6.8%), where treatment with angiotensin-converting enzyme inhibitor was common (Table 3) . β-Blockers were globally prescribed to 41.8% of the patients, ranging from 21.7% in Africa to half of the patients in North America and Western and Eastern Europe. A quarter of the patients had digoxin, ranging from 12.7% in Western Europe to more than one-third of patients in India and Africa; and, in total, 8.2% had verapamil or diltiazem, with only 2.0% in Africa up to 18.5% in North America (Table 3) . Of the specific antiarrhythmic drugs, amiodarone was most common with 8.7% globally, although with a large variation from ≤5% in North America, Western Europe, the Middle East, and Africa to >5% in South America and Eastern Europe. All other antiarrhythmics (eg, flecainide, propafenone, sotalol, disopyramide, dofetilide, and quinidine) were globally prescribed in ≤2% of the patients, albeit with some regional variations, most prominently, with higher rates of propafenone in Eastern Europe (4.4%) and China (3.9%) and sotalol in Eastern Europe (3.4%; Table 3 ). Overall, less than one-third of the patients had lipid-lowering drugs, most commonly statins (26.3%), ranging from only 6.2% in Africa to 42.2% in North America ( Table 3) .
The proportion of patients with a history of hypertension who did not receive antihypertensive therapy was only 3.7% in North America, but was >10% in Southeast Asia, Africa, and Eastern Europe (Table 3) . Among patients with a history of hypertension, the baseline systolic blood pressure was highest in Africa (142.2, SD 29.0 mm Hg), Eastern Europe (140.5, SD 22.7 mm Hg), and China (140.0, SD 23.2 mm Hg). Similarly, the prevalence of left ventricular hypertrophy among patients with hypertension was highest in Eastern Europe (46.2%) and Africa (38.1%; Table 2 ).
The majority (51.9%) of patients with heart failure received treatment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, ranging from more than two-thirds of patients in South America to only one-third of patients in India and China, whereas, overall, 45.6% of patients received β-blockers for the treatment of heart failure, ranging from almost two-thirds in North America and Western Europe to only one-fifth of patients in Africa (Table 3) .
Exploration of Regional Differences in Patient Age
Given the significant regional differences in the prevalence of rheumatic and infectious diseases and that patients with these conditions tend to be substantially younger than those with cardiovascular disease and hypertension, the baseline demographics and prevalence of cardiovascular conditions were reanalyzed for each region, after excluding patients with rheumatic heart disease, HIV, active tuberculosis, endomyocardial fibrosis, Chagas disease, and pericarditis (Table I in the online-only Data Supplement). Exclusion of these patients resulted in more similar distribution of age across regions, but patients in India, the Middle East, and Africa were still at least 7 years younger.
Discussion
This is one of the largest prospective registry studies of AF and the first global registry to include unselected patients in the emergency department, with a significant number of individuals from middle-and low-income countries, and representing all inhabited continents. It demonstrates a wide regional variation in the risk factors, concomitant diseases, and treatment of AF. Patients with AF from middle-and low-income countries are significantly younger than those from high-income countries, the diseases associated with their AF are quite different, and these patients are less likely to be managed according to published AF guidelines. 21 Despite large regional variations in prevalence, hypertension is the most common risk factor for AF globally. Thus, to prevent AF, more effective strategies to diagnose, treat, and control hypertension need to be implemented. 23 This need is greatest in Eastern Europe and Africa, where hypertension is most likely to be untreated and poorly controlled and where ≈40% of hypertensive patients have evidence of left ventricular hypertrophy, a marker of prolonged uncontrolled hypertension and of poor outcomes. In addition, ≈60% of individuals in these 2 regions had a history of heart failure and systolic left ventricular dysfunction, which might be secondary to their predisposing conditions for AF, typically hypertension and valvular heart disease. Earlier identification and treatment of these risk factors in the community could lead to improved patient outcomes and reduced acute-care costs. 24 Rheumatic heart disease remains an important cause of AF in Africa, China, the Middle East, and particularly in India, where it is present in nearly one-third of patients with AF. In fact, the true prevalence in these regions is probably higher, because this registry did not include routine echocardiography, which is sensitive for the diagnosis of rheumatic heart disease. 25 Although rheumatic heart disease is strongly associated with lower socioeconomic status, 26 low-cost strategies to prevent the development and recurrence of rheumatic heart disease could have a great impact on preventing the development of AF and its complications. [27] [28] [29] The average age of patients with AF and rheumatic heart disease in this registry was 52 (SD 22) years and 66.2% were women, many of whom had childbearing potential. Thus, the consequences of AF-related stroke are great in this cohort, but so are the challenges for stroke prevention. Although patients with rheumatic heart disease are one of the highest-risk groups for stroke, virtually all research into stroke risk stratification schemes and randomized trials of anticoagulant therapy have excluded patients with rheumatic heart disease or severe heart valve disorders. 12, [14] [15] [16] 30 Stroke prevention therapies, including the new oral anticoagulants, should be evaluated in patients with rheumatic heart disease. To be feasible and relevant, these studies should be conducted in the regions where rheumatic AF is most prevalent.
AF remains a major cause of death, stroke, and disability worldwide. 2, 7, 31, 32 Over the past 15 years, many important clinical studies have improved our ability to prevent the morbidity and mortality of AF. 10, 12, [14] [15] [16] 33 The benefits of this research have been realized largely by individuals in high-income countries, for whom the research was targeted. The appropriate use of oral anticoagulation in patients with nonvalvular AF and additional risk factors can reduce the rate of stroke by two-thirds or more. 12, 14, 16 However, in the present study population, oral anticoagulation was prescribed for only 58% of patients worldwide with a previous history of nonrheumatic AF and a CHADS 2 score of ≥2. The use of oral anticoagulants in these AF patients at risk for stroke was ≤40% in Eastern Europe, India, and Africa where access to INR testing and follow-up are limited, and was only 11% in China where physicians have concerns about the rate of warfarin-related intracranial hemorrhage, and disagreement exists as to the appropriate therapeutic ranges of INR. 34, 35 INR control was also particularly poor in these regions, but only approached desired levels 36 in Western Europe. Low-cost generic strategies may be considered to overcome these hurdles in low-and middle-income countries by using nonphysician health workers especially at local community centers or even in people's homes, where INRs can be checked once a month with point-of-care devices purchased in bulk by governments and provided to each clinic. The advent of novel oral anticoagulants 14, 16 may help to overcome some of these barriers; however, their current high costs may make these novel drugs affordable for only a select group of individuals who are either wealthy or have private health insurance. For the majority of patients in these regions, strategies to diagnose hypertension early and improve its control, improve the management of warfarin, 37 or improve the use of combination antiplatelet medications. 38 Although the combination of aspirin and clopidogrel is less effective than oral anticoagulants, this treatment does not require regular monitoring and may be affordable, thereby a wider use may not be ideal but better than no stroke prevention treatment. The region-specific differences identified in this registry may also give opportunities to improve care, which should lead to increased physician and patient awareness through educational strategies, management and prevention strategies, and ultimately changes in public policy to maximize benefit in low-and middle-income countries. Government-level policy changes are needed to improve hygiene and access to affordable health care to control the growing incidence of rheumatic heart disease. Strategies may also include screening for rheumatic heart disease and systems of care to include routine ECGs once in 5 years in elderly patients or patients with specific risk factors for AF, such as hypertension, vascular disease, or valve disease.
Limitations and Strengths
Because this registry did not include patients without AF, it cannot provide a direct measure of AF prevalence in the emergency department or determine the population-attributable risk for the various AF risk factors. However; the latter have been well documented in earlier studies 9, 39 and the current study's focus is on comparing the relative prevalence of established risk factors between global regions. The current registry did not include consecutive patients; however, patient characteristics are similar to smaller regional registries that did. 7, 8 Although this registry is not population based, its recruitment of primary care patients from emergency departments avoids many of the biases of other multinational registries that enrolled patients from specialist physicians' offices. 40 Finally, echocardiography was not performed as part of the protocol and was not uniformly done throughout the world; thus, the ascertainment of left ventricular hypertrophy and valvular disease may have differed between regions. However, the regions with the highest reported prevalence of these 2 conditions were among those with the lowest use of cardiac technology, 41 including echocardiography; thus, the regional differences observed in this registry were, if anything, an underestimate of the disparity.
Despite these limitations, the RE-LY AF registry has several strengths, including its large size and its broad global representation of countries, including many low-and middleincome countries, many of which have never been included in previous registries or clinical trials of patients with AF.
Conclusions
There is wide regional variation in the age, the presence of stroke risk factors, concomitant diseases, and the treatment of patients with AF. Improving outcomes globally requires an understanding of this variation, and the conduct of research focused on AF associated with different underlying conditions and of treatment of AF and predisposing conditions in different socioeconomic settings.
Sources of Funding
The RE-LY AF Registry was funded by an unconditional grant from Boehringer-Ingelheim. 1. In the paragraph "Medication in patients with a prior history of AF or other Predisposing
Conditions", last sentence in page 1570, the figure 44.9% is incorrect. The correct sentence should be: "In patients with a previous history of AF and a CHADS2 risk score of ≥2 but without a history of rheumatic fever, 44.1% were treated with an oral anticoagulant at the time of presentation to the emergency department:" 2. Figure 2 should depict oral anticoagulation use in patients with prior Atrial Fibrillation (AF) and rheumatic heart disease (black bars), and patients with prior AF and CHADS2 score ≥2 but without rheumatic heart disease (grey bars). By mistake figure 2 in the original publication incorrectly depicted oral anticoagulation use in all patients with history of rheumatic heart disease, irrespective of prior AF, in the black bars; and all patients with CHADS2 score ≥2, irrespective of prior AF, in the grey bars.
